Company intelligence / Profile preview
Intellect Neurosciences, Inc.
Englewood Cliffs, New Jersey, USAintellectneurosciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OX1 has demonstrated safety in human Phase I trials for Friedreich’s Ataxia and potentially other neurodegenerative conditions. Other pipeline assets are at preclinical or pending clinical trial stages targeting Alzheimer’s disease and retinal/neurodegenerative disorders.[1]
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small moleculesMonoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Therapeutic vaccines
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Medical Research Council TechnologySouth Alabama Medical Science FoundationNew York UniversityAHP Manufacturing BVNorthwestern University
Beyond the preview
Go deeper on Intellect Neurosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intellect Neurosciences, Inc..